QP-Brain®
Brain volumetry and white matter hyperintensity analysis for accelerated diagnosis
Software · Cloud SaaSCompany source
Company profile
About Quibim
Quibim is a medical imaging AI company that transforms complex imaging data into actionable clinical predictions. The company has built a comprehensive cloud-based platform that extracts key radiomics drivers from large-scale imaging data registries to support drug development, clinical research, and patient care. Quibim's technology portfolio includes QP-Insights®, a platform for managing, harmonizing, and analyzing multi-omics and imaging data, alongside specialized medical device software products for specific clinical applications. Their QP-Prostate® solution streamlines prostate MRI interpretation with PI-RADS compliance, while QP-Brain® provides volumetric analysis and white matter hyperintensity assessment. QP-Liver® quantifies fat and iron concentration for comprehensive liver disease evaluation, and QP-Breast® and QP-Lung® address additional clinical needs. The company serves three primary markets: Life Sciences partnerships with biopharma companies for drug development acceleration, healthcare providers seeking clinical decision support tools, and research institutions conducting imaging biomarker discovery. Quibim's platform processes data from over 100,000 de-identified cancer patients and manages millions of research imaging studies across sites worldwide. Built on Microsoft Azure with ISO 27001:2022 certification, the platform ensures HIPAA and GDPR compliance with encryption during storage, transfer, and at file-level. Quibim's mission centers on pioneering value-based, evidence-driven solutions that identify clinical trial candidates, predict treatment response, and monitor adverse events through advanced AI models.
Company description Quibim official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at Quibim?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- B-Cell lymphoma
- Brain disorders
- Breast cancer
- Liver disease (steatosis, iron overload)
- Lung disease
- Neuroblastoma
- Prostate cancer
Who it serves
- Biopharma companies
- Clinical trial sites
- Healthcare providers
- Research institutions
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: EHR systems, PACS systems.
Geographic context
MarketsCanada · Germany · Global · Spain · United States (New York)
Company sourceOfficial website
Company milestones
Platform expansion
QP-Prostate® received Health Canada Licence (June 2024); Selected by New York for strategic AI program (May 2024); Partnership with Vara for breast cancer screening in Spain (April 2024)
Partnerships
Recorded partners
- New York strategic AI program participant
- Vara (Germany) for breast cancer screening AI in Spain
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
QP-Breast®
AI solution for breast cancer screening and diagnosis
Software · Cloud SaaSCompany source
QP-Insights®
Cloud platform for managing, storing, and analyzing large-scale multi-omics data and medical images
Platform · Cloud SaaSCompany source
QP-Liver®
Post-processing solution for liver disease management with fat and iron quantification
Software · Cloud SaaSCompany source
QP-Lung®
AI-powered lung imaging analysis solution
Software · Cloud SaaSCompany source
QP-Prostate®
AI solution for prostate MRI that integrates with PACS to streamline radiologist workflow
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Experiences on using the CHAIMELEON secure processing environment in an open competition addressing five AI challenges.Computer methods and programs in biomedicine · Nov 1, 2026
Correction: Toward a standardized and interoperable imaging biomarker catalog.Insights into imaging · Jul 16, 2026
Integrating Participatory Social Innovation Into Requirements Engineering for AI Health Care Solutions: Case Study.Journal of medical Internet research · Jul 3, 2026
Toward a standardized and interoperable imaging biomarker catalog.Insights into imaging · Jun 9, 2026
Correction: Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.Insights into imaging · Jun 2, 2026
A pre-trained foundation model framework for multiplanar MRI classification of extramural vascular invasion and mesorectal fascia invasion in rectal cancer.Insights into imaging · May 22, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
100+ sites worldwide
Global deployment of Quibim platforms
100,000+ de-identified cancer patients
Patient registry size
Millions of research imaging studies
De-identified research imaging data processed
Vara partnership (Germany/Spain)
Bringing Europe's leading breast-cancer screening AI to Spain through partnership
Expanded breast cancer screening AI capabilities to Spanish market
B-Cell lymphoma CAR-T therapy study
Predicting survival, neurotoxicity, and response in B-Cell lymphoma patients treated with CAR-T therapy using imaging features-based model
Developed predictive model for survival, neurotoxicity, and treatment response
Neuroblastoma risk stratification study
Empowering neuroblastoma risk stratification through AI algorithms
Enhanced risk stratification capabilities using AI
Diffuse large B cell lymphoma study
Prognostic value assessment of genetic alterations and 18F-FDG PET/CT imaging features in diffuse large B cell lymphoma
Established prognostic value of imaging features combined with genetic data
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Quibim
Recent articles published on Quibim's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.